Related Experiment Video
Updated: Mar 31, 2026
10:17
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
7.5K
INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
Gabriela Esteves Leghi1, Fernanda Aparecida Domenici2, Helio Vannucchi3
1Divisão de Nutrição Clínica, Departamento de Medicina Interna, Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, SP, BR.
Arquivos De Gastroenterologia
|October 22, 2015
Summary
Nonalcoholic steatohepatitis (NASH) patients show altered glucose and lipid metabolism, and oxidative stress markers compared to controls. Obesity alone does not explain all observed biochemical changes in NASH.
Area of Science:
- Hepatology
- Metabolic Syndrome
- Oxidative Stress
Background:
- Nonalcoholic steatohepatitis (NASH) is the liver manifestation of metabolic syndrome, linked to insulin resistance, hypertension, obesity, and metabolic dysregulation.
- Obesity and oxidative stress are key factors in NASH development and progression.
Purpose of the Study:
- To investigate the presence and association of obesity and oxidative stress in nonalcoholic steatohepatitis (NASH).
Main Methods:
- A comparative study included 15 NASH patients and 15 BMI-matched controls.
- Evaluated nutritional status and biochemical markers including glucose, liver enzymes, lipids, leptin, and oxidative stress indicators (superoxide dismutase, glutathione peroxidase, vitamins C and E, catalase, 8-isoprostane).
Main Results:
- NASH patients exhibited elevated fasting glucose, liver enzymes, triglycerides, and superoxide dismutase.
- NASH individuals also showed lower glutathione peroxidase levels compared to controls.
Conclusions:
- Obesity alone is insufficient to induce all studied biomarker alterations in nonalcoholic steatohepatitis (NASH).
- While most oxidative stress markers were similar, NASH subjects may experience slightly greater oxidative stress impact.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
283
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
283
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
381
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
381
01:26Stress Prevention and Stress Management Techniques IV
326
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
326
01:21Drug Dosing: Obese Patients
341
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
341
01:30Coronary Artery Disease I: Introduction
1.6K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K